Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Michigan › Detroit
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Detroit, MI
15 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi sekitar Detroit (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Menerima pesertaFase 3
- Karmanos Cancer Institute, Detroit
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Menerima pesertaStudi observasional
- Karmanos Cancer Institute, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Menerima pesertaFase 2/3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of DM005 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Henry Ford Health System, Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 129, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di kota lain
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- New York City, NY39 studi
- Nashville, TN39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Chicago, IL26 studi
- Philadelphia, PA26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- Pittsburgh, PA22 studi
Studi lain di Detroit
- Kanker Paru Non-Sel Kecil44 studi
- Kanker Payudara33 studi
- Kanker (semua jenis)29 studi
- Kanker Kolorektal26 studi
- Kanker Ovarium26 studi
- Kanker Metastatik24 studi
- Kanker Prostat22 studi
- Kanker Endometrium21 studi
- Kanker Paru20 studi
- Mieloma Multipel19 studi
- Kanker Lambung16 studi
- Leukemia Mieloid Akut14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.